Pricing Log in Create free account
Friday 6 November 2026 Export RPID’s income statement to Excel — free account

Rapid Micro Biosystems, Inc.

RPID Healthcare Medical Devices

Rapid Micro Biosystems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.6 million, up 19.7% from fiscal 2024.

Revenue
+10.9%
EPS
0.00%
Free cash flow
−24.0%

Quarter to June 2026, against a year earlier

0.64 0.02 +3.23%
Market cap
$31.1M
P/E
0.0×
Fwd P/E
−0.8×
Dividend yield
—
F-score
3/9
Altman Z
−8.86
Beneish M
−5.06
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 1.14
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — 1 7 3 — — — — — — — —
Insider Ownership 45.44%

Capital & Financial Ratios $m

Size
Market Cap 31.10
Revenue ttm 35.18
Net income ttm (51.20)
Free cash flow ttm (40.39)
Net debt Q (0.63)
Valuation
P/E 0.00
Forward P/E (0.78) (negative: loss-making)
Price / sales 0.87
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.72
Financial health
Current ratio Q 2.55 (at or above 1.5: strong)
Debt / equity Q 1.08
Interest coverage Q (19.07)
Growth
Revenue growth Q +10.91% (above 0%: growing)
Operating income growth Q −1.43% (below 0%: shrinking)
EPS, this year +10.24%
EPS, next year A +24.14% (at or above 15%: strong)
Revenue, next year A +16.95% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +23.23% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.8×, against a ten-year median of 0.8×; over the ten years it ranged from −3.3× in 2022 to 22.6× in 2021.
P/S against its own 10 years 4.12%
10-year low 10-year high
P/B against its own 10 years 66.04%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 92 51 38 20
Receivables 6 8 3 6
Inventory 20 20 18 19
Other — — — —
120 81 61 46
2023 2024 2025 Q'26
Payables 2 3 4 5
ST’ Debt — — — —
Other — — — —
19 18 18 18

Compound Annual Growth %

10y 5y 3y
Sales — 15.88% 25.15%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% (41.30%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.26 Actual −0.27

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.26 −0.26 Met by 0.00
Q4 FY25 −0.23 −0.28 Miss by 0.05
Q1 FY26 −0.25 −0.31 Miss by 0.06
Q2 FY26 −0.26 −0.27 Miss by 0.01
Q3 FY26 −0.20 — Reports 6 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.31) (0.27) — — —
’25 (0.26) (0.27) (0.26) (0.28) (1.05)
’24 (0.31) (0.29) (0.26) (0.22) (1.08)
’23 (0.32) (0.33) (0.31) (0.26) (1.22)
’22 (0.35) (0.31) (0.38) (0.39) (1.43)
’21 (34.48) (20.01) (0.71) (0.35) (3.94)
’20 (22.65) (26.22) (23.78) (30.63) (126.11)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 8 8 — — —
’25 7 7 8 11 34
’24 6 7 8 8 28
’23 5 5 6 6 23
’22 4 4 5 4 17
’21 5 6 7 5 23
’20 3 3 5 5 16
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (15) (13) — — —
’25 (9) (10) (9) (3) (31)
’24 (16) (10) (9) (10) (44)
’23 (17) (9) (10) (9) (45)
’22 (17) (15) (15) (12) (59)
’21 (11) (12) (19) (13) (55)
’20 (8) (9) (9) (5) (31)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (15) (12) — — —
’25 (9) (10) (9) (3) (32)
’24 (16) (11) (9) (10) (46)
’23 (17) (9) (10) (10) (47)
’22 (19) (17) (17) (12) (65)
’21 (12) (12) (20) (15) (58)
’20 (8) (9) (9) (5) (32)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 17 16 23 17 23 28 34 35 +12.6% 39 46 60 +21.5%
Gross margin, % — — — (1.42) (50.20) (33.32) (49.85) (24.36) (0.39) 3.12 5.55 +4.5 pt
EBT — — — (21) (37) (73) (61) (52) (47) (47) (51) +14.6%
EBT margin, % — — — (125.63) (229.79) (316.09) (358.27) (232.85) (167.08) (140.18) (145.34) (14.5) pt
Net income — 0 — (21) (37) (74) (61) (52) (47) (47) (51) n/m
Per share, $
Per share, $ Revenue — — — 47.72 44.78 1.17 0.40 0.52 0.64 0.75 0.73 (49.9%)
Earnings — — — (76.72) (126.11) (3.94) (1.43) (1.22) (1.08) (1.05) (1.12) (51.1%)
Cash flow — — — (61.12) (86.34) (2.78) (1.38) (1.05) (1.01) (0.70) (0.83) (52.6%)
Capex — — — (4.90) (1.92) (0.16) (0.16) (0.04) (0.03) (0.02) (0.01) (60.4%)
Free cash flow — — — (66.02) (88.26) (2.94) (1.54) (1.09) (1.04) (0.71) (0.84) (53.0%)
Book value — — — (238.66) (353.78) 11.17 3.87 2.74 1.73 0.74 0.37 n/m
Shares, m — — — 0 0 20 42 43 44 45 46 +124.8%
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — — 0.69 0.69 9.06 3.02 1.74 1.40 3.86 0.87 2.9
P/B — — — 0.00 0.00 0.95 0.32 0.33 0.52 3.90 1.72 0.9
EV/Sales — — — (2.79) (2.79) 0.75 (2.90) (2.06) (0.18) 3.28 0.85 (1.0)
EV/FCF — — — 1.59 1.59 (0.30) 0.76 0.99 0.11 (3.45) (0.74) 0.2
Cash, $m
Cash, $m Operating cash flow — — — (21) (31) (55) (59) (45) (44) (31) (40) +6.6%
Capex — — — (2) (1) (3) (7) (2) (1) (1) 0 (10.9%)
Free cash flow — — — (23) (32) (58) (65) (47) (46) (32) (40) +5.7%
Balance, $m
Balance, $m Working capital — — — 13 47 200 120 101 63 43 28 +21.8%
Net debt — — — 5 (20) (193) (101) (92) (51) (19) (1) n/m
Shareholders’ equity — — — (83) (127) 221 164 118 75 33 18 n/m
Returns, %
Returns, % ROA — — — (168.01) (88.94) (50.15) (28.16) (31.41) (38.81) (54.47) (76.40) +113.5 pt
ROIC — — — 0.00 0.00 (105.87) (62.99) (136.30) (126.72) (214.45) (181.64) (214.4) pt
ROE — — — 25.40 43.15 (166.07) (31.58) (37.19) (48.50) (86.82) (141.65) (112.2) pt
People
People Employees — — — — 160 202 177 193 163 171 — +1.3%
Revenue/emp, $m — — — 0.00 0.10 0.12 0.10 0.12 0.17 0.20 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Rapid Micro Biosystems, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
XTNT Xtant Medical Holdings, Inc. $42.1M — (loss-making) — (loss-making) −34.96% (below 0%: shrinking) n/m −881.96% (below 0%: shrinking) 57.88% (39.81%) Compare
CVRX CVRx, Inc. $39.2M — (loss-making) — (loss-making) −5.84% (below 0%: shrinking) n/m −9.91% (below 0%: shrinking) 86.74% (94.31%) Compare
TELA TELA Bio, Inc. $35.2M — (loss-making) — (loss-making) −4.49% (below 0%: shrinking) n/m −17.72% (below 0%: shrinking) 72.77% (48.12%) Compare
ELUT Elutia Inc. $33.3M 0.6× — (loss-making) −11.65% (below 0%: shrinking) n/m −2.52% (below 0%: shrinking) 59.62% (327.85%) Compare
RPID Rapid Micro Biosystems, Inc. $31.1M — (loss-making) — (loss-making) +10.91% (above 0%: growing) n/m −23.97% (below 0%: shrinking) 15.05% (152.99%)
QTI QT Imaging Holdings, Inc. $30.3M — (loss-making) — (loss-making) +103.20% (above 0%: growing) n/m −236.31% (below 0%: shrinking) 41.16% (25.07%) Compare
NSYS Nortech Systems Incorporated $30.0M 28.4× 17.5× +9.34% (above 0%: growing) −8.33% (below 0%: shrinking) −1,567.16% (below 0%: shrinking) 17.00% 1.86% Compare
NSPR InspireMD, Inc. $29.7M — (loss-making) — (loss-making) −0.39% (below 0%: shrinking) n/m −26.00% (below 0%: shrinking) (43.70%) (815.64%) Compare
NNOX Nano-X Imaging Ltd. $19.6M — (loss-making) — (loss-making) +36.71% (above 0%: growing) n/m −21.37% (below 0%: shrinking) (1,050.87%) (1,334.91%) Compare
Median of peers $31.8M — — −2.44% — −23.68% 49.52% (71.22%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 8 April 2026

Ownership

Directors and executive officers, together 12.70%
Entities affiliated with Bain Capital Life Sciences Investors, LLC 20.44%
Entities affiliated with Kennedy Lewis Investment Management LLC 12.55%
Entities affiliated with Longitude Capital Partners II, LLC 9.76%
Robert Spignesi 6.73%
Entities affiliated with Endeavour Medtech Growth II LP 5.47%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Rapid Micro Biosystems, Inc. (RPID) Latest News

22 Oct

Impact 4 · · Insider Monkey

20 Oct

Impact 3 · · GlobeNewswire

14 Aug

Impact 3 · · The Motley Fool transcript

7 Aug

Impact 4 · transcript
Impact 3 · · Moby transcript
Impact 3 · · MarketBeat
Impact 3 ·

18 May

Impact 3 · · GlobeNewswire

14 May

Impact 4 · · GuruFocus.com
Impact 3 · · Moby transcript
Impact 3 · · MarketBeat

13 May

Impact 4 · · Benzinga transcript
Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

14 Apr

Impact 3 ·

21 Mar

Impact 4 · · MarketBeat

12 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · Moby
Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire
Impact 3 · · MarketBeat

12 Feb

Impact 4 · · Simply Wall St.

13 Jan

Impact 4 · · GlobeNewswire

7 Jan

Impact 3 ·

5 Jan

Impact 3 · · Simply Wall St.

21 Dec

Impact 3 ·

10 Nov

Impact 4 · · Simply Wall St.

8 Nov

Impact 4 · · GuruFocus.com

7 Nov

Impact 4 · · GlobeNewswireGuruFocus.comGuruFocus.comStockStoryAssociated Press FinanceStockStoryGuruFocus.comGuruFocus.com
Impact 3 · · ZacksZacks
stockrow.com/RPID · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com